Tender Details

Country: USA
Summary: Acquisition of Radioactive products PLUVICTO and LUTATHERA
UST Ref No: 133249695
Deadline: 11 Jan 2026
Financier: Self Financed
Purchaser Ownership: Government
Tender Value: Refer Document
Notice Type: Tender
Document Ref. No.:
Purchaser's Detail:
Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
Login to see details
Description:
The Defense Health Agency (DHA), Healthcare Contracting Division Northeast (HCD-NE), on behalf for the Department of Radiology Department located at Walter Reed National Military Medical Center (WRNMMC), 8901 Wisconsin Avenue, Bethesda, MD 20889, under the statutory authority of the Federal Acquisition Regulation (FAR) 6.302-l(a) (2) (iii) (b), sole source, for the requirement for radioactive products (PLUVICTO and LUTATHERA) used for imaging patient-s disease, intends to award a Firm-Fixed Price, to Novartis Pharmaceuticals Corporation.
Manufactured radioactive products (PLUVICTO and LUTATHERA) used for imaging patient-s disease must be U.S. FDA Approved.
Novartis Pharmaceuticals Corporation, (CAGE: 04520), 59 Route 10, East Hanover, NJ 07936 is the FDA Approved Manufacturer for PLUVICTO and LUTATHERA. The total cost for the Purchase Order is estimated at $578,754.32. The associated NAICS code applicable to this requirement is 325412 - Pharmaceutical Preparation Manufacturer.
This notice of intent to award a competitive Purchase Order is not a request for competitive proposals. There will be no Request for Quote (RFQ) or Solicitation available for competition. Phone calls will not be accepted. This notice is not a request for competitive quotes; however, the government will consider responses to this notice within five (5) days of this posting. Interested parties, may express their interest, and provide a capabilities statement NLT January 11, 2026, at 7:00 AM EST. The point of contact for this action is Malcolm Dodson, Contract Analyst, who can be reached at Malcolm.dodson.ctr@health.mil. A determination by the government not to compete this requirement based upon responses to this notice is solely within the discretion of the government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement.
Documents:

If you are registered member, kindly login to view full details of this tender notice:

Acquisition of Radioactive products PLUVICTO and LUTATHERA - USA Tender

The DEPT OF DEFENSE | DEFENSE HEALTH AGENCY (DHA), a Government sector organization in USA, has announced a new tender for Acquisition of Radioactive products PLUVICTO and LUTATHERA. This tender is published on USARFP under UST Ref No: 133249695 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2026-01-11.

The estimated tender value is Refer Document, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.